Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE…
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE…
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE…
Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…
Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…
Pioneering Precision Engineering to Transform Global Therapeutics DeliveryVANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded…
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company…
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival…